- Join Us
- About the Event
- About CRI
- Why Immunotherapy
Thank you for visiting my fundraising page!
Why I Ride - I am riding in the second Answer to Cancer ride in honor of my dad, Bob Shapiro, who passed away from brain cancer in 2008. Cancer unfairly deprived him of the chance to fight important unfinished battles. Others should not have to face the same.
Goals - Last year I rode 27 miles and was the 13th fastest rider at that distance, so I decided to challenge myself further this year. I plan to ride 55 miles -- the farthest I have ever ridden a bike. With ambitious athletic goals come ambitious fundraising goals. Last year we raised almost $4,000 and I'm aiming to best that with your help.
Why CRI? - The Cancer Research Institute (CRI) is working hard to develop new and promising immunotherapy-based treatments for all cancer patients. (Brain cancer is one type of cancer where immunotherapy has shown great promise.) CRI has funded over 120 clinical trials and six immunotherapy drugs have received FDA approval. And that is just the tip of the iceberg - powerful weapons remain to be discovered to fight all cancers, including those that are currently death sentences, like my dad's.
Worthy Charity - CRI has one of the best Charity Navigator ratings of any cancer organization (94.69 with a 4-star rating), and meets all 20 of the Better Business Bureau's Standards for Charity Accountability. So your donation will be used as intended - while the American Cancer Society, for example, spends over 40% annually on non-program overhead expenses, CRI uses a remarkably low 14%, leaving 86% for program expenses.
Matching Contributions - To incentivize generous contributions, I will personally match 25% of all donations made to my page (up to $5,000).
Thank you! - Thank you in advance for your consideration of CRI and your support for my ride.
Stephen, diagnosed with metastatic colorectal cancer at 28, enrolled in a clinical trial for a checkpoint inhibitor, a type of immunotherapy.
Read Stephen's Story
Deborah, who was treated with the immunotherapy Yervoy" in combination with radiation for stage III melanoma, participated in the 2016 Answer to Cancer cycling event to raise funds for CRI.
Read Deborah's Story
In 2012, life-long Tennessean Philip was shocked to learn that he had kidney cancer. Not satisfied with the chemotherapy options presented to him, Philip enrolled a clinical trial for the immunotherapy nivolumab (Opdivo").
Read Philip's Story